B cells are prolific producers of these autoantibodies, and as such have been targeted by numerous antirheumatic therapies. One of these therapies, rituximab, a chimeric monoclonal antibody ...

leading to the formation of B cells that lose their tolerance to the body's tissues and produce autoreactive (self-attacking) antibodies. The findings may have treatment implications for ...

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free remission from autoimmune diseases observed after treatment ...

Conclusions: ATG1144 specifically binds to human CD24 with high sensitivity as demonstrated by IHC staining. The development and validation of the method have been finalized using Leica Bond III ...

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ:AZN) for up to $1 billion, on a cash and debt-free basis, it said on Monday. The deal includes an initial ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and Gracell Biotechnologies.